1,190
edits
Changes
Translocations et al. in Hematological Cancers (view source)
Revision as of 14:21, 31 July 2016
, 14:21, 31 July 2016→Translocations Long List
Line 30:
Line 30:
|-
|-
|[[t(1;5)(q22;q33)]]
|[[t(1;5)(q22;q33)]]
−|[[MPD with eosinophilia]],[[ CEL]],[[ B-ALL]]
+|[[MPD]],[[ CEL]],[[ B-ALL]]
|[[PDE4DIP-PDGFRB]]
|[[PDE4DIP-PDGFRB]]
|-
|-
Line 42:
Line 42:
|-
|-
|[[t(1;14)(q21;q32)]]
|[[t(1;14)(q21;q32)]]
−|[[B-ALL]],[[ NHL]]
+|[[B-ALL]],[[NHL]]
|[[IGH-BCL9]],[[IGH-FCGR2B]],[[IGH-FCRL4]],[[IGH-MUC1]]
|[[IGH-BCL9]],[[IGH-FCGR2B]],[[IGH-FCRL4]],[[IGH-MUC1]]
|-
|-
Line 58:
Line 58:
|-
|-
|[[t(2;5)(p23;q35)]]
|[[t(2;5)(p23;q35)]]
−|[[ALCL]],[[ NHL]]
+|[[ALCL]],[[NHL]]
|[[NPM1-ALK]]
|[[NPM1-ALK]]
|-
|-
|[[t(2;8)(p12;q24.1)]]
|[[t(2;8)(p12;q24.1)]]
−|[[BL]],[[ B-ALL]],[[ NHL ]]
+|[[BL]],[[ B-ALL]],[[NHL]]
|[[MYC]]
|[[MYC]]
|-
|-
Line 73:
Line 73:
|
|
|-
|-
−|[[Translocation t(3;3)(q21;q26.2) and Inversion inv(3)(q21q26.2)|t(3;3)(q21;q26.2) ]]
+|[[Translocation t(3;3)(q21;q26.2) and Inversion inv(3)(q21q26.2)|t(3;3)(q21;q26.2)]]
|[[MDS]],[[AML]]
|[[MDS]],[[AML]]
|[[RPN1-MECOM(EVI1)]]
|[[RPN1-MECOM(EVI1)]]
Line 98:
Line 98:
|-
|-
|[[t(4;5;5)(q23;q31;q33)]]
|[[t(4;5;5)(q23;q31;q33)]]
−|[[chronic basophilic leukemia]]
+|[[Chronic Basophilic Leukemia]]
|[[PRKG2-PDGFRB]]
|[[PRKG2-PDGFRB]]
|-
|-
Line 114:
Line 114:
|-
|-
|[[t(5;12)(q33;q24)]]
|[[t(5;12)(q33;q24)]]
−|[[MPD with eosinophilia ]]
+|[[MPD]]
|[[GIT2-PDGFRB]]
|[[GIT2-PDGFRB]]
|-
|-
|[[t(5;12)(q33;p13)]]
|[[t(5;12)(q33;p13)]]
−|[[CMML]],[[ MDS]],[[ MPD]]
+|[[CMML]],[[MDS]],[[MPD]]
|[[ETV6(TEL)-PDGFRB]]
|[[ETV6(TEL)-PDGFRB]]
|-
|-
|[[t(5;14)(q33;q24)]]
|[[t(5;14)(q33;q24)]]
−|[[MPD]],[[ atypical MPD]]
+|[[MPD]],[[MPD]]
|[[NIN-PDGFRB]]
|[[NIN-PDGFRB]]
|-
|-
Line 130:
Line 130:
|-
|-
|[[t(5;15)(q33;q22)]]
|[[t(5;15)(q33;q22)]]
−|[[CMML atypical MPD]]
+|[[CMML]],[[MPD]]
|[[TP53BP1-PDGFRB]]
|[[TP53BP1-PDGFRB]]
|-
|-
Line 142:
Line 142:
|-
|-
|[[der(5;17)(p10;q10)]]
|[[der(5;17)(p10;q10)]]
−|[[MDS]],[[ AML]]
+|[[MDS]],[[AML]]
|[[NPM1(NPM)-RARA]]
|[[NPM1(NPM)-RARA]]
|-
|-
Line 150:
Line 150:
|-
|-
|[[t(5;17)(q33;p13)]]
|[[t(5;17)(q33;p13)]]
−|[[CMML]],[[ atypical MPD]]
+|[[CMML]],[[MPD]]
|[[RABEP1-PDGFRB ]]
|[[RABEP1-PDGFRB ]]
|-
|-
Line 162:
Line 162:
|-
|-
|[[t(6;11)(q27;q23) ]]
|[[t(6;11)(q27;q23) ]]
−|[[AML]],[[ t-AML]],[[ T-ALL]]
+|[[AML]],[[ t-AML]],[[T-ALL]]
|[[KMT2A-MLLT4]]
|[[KMT2A-MLLT4]]
|-
|-
Line 173:
Line 173:
|[[IGH-MYC]]
|[[IGH-MYC]]
|-
|-
−|[[t(8;16)(p11.2;p13.3) A]]
+|[[t(8;16)(p11.2;p13.3)]]
|[[AML]],[[t-MDS]]
|[[AML]],[[t-MDS]]
|[[KAT6A(MYST3)-CREBBP(CBP)]]
|[[KAT6A(MYST3)-CREBBP(CBP)]]
|-
|-
|[[t(8;21)(q22;q22) A ]]
|[[t(8;21)(q22;q22) A ]]
−|[[AML M2 mostly]],[[ rarely M1]],[[ M4]]
+|[[AML]]
|[[RUNX1(AML)-RUNX1T1(ETO)]]
|[[RUNX1(AML)-RUNX1T1(ETO)]]
|-
|-
|[[t(8;22)(q24.1;q11.2) ]]
|[[t(8;22)(q24.1;q11.2) ]]
−|[[BL]],[[ B-ALL]],[[ NHL]],[[ MM]]
+|[[BL]],[[ B-ALL]],[[NHL]],[[ MM]]
|[[IGL-MYC]]
|[[IGL-MYC]]
|-
|-
Line 194:
Line 194:
|-
|-
|[[t(9;14)(p13;q32)]]
|[[t(9;14)(p13;q32)]]
−|[[MM]],[[CLL]],[[DLBCL]],[[ FL]],[[MCL splenic MZL]]
+|[[MM]],[[CLL]],[[DLBCL]],[[FL]],[[MCL splenic MZL]]
|[[PAX5-IGH]]
|[[PAX5-IGH]]
|-
|-
|[[t(9;22)(q34;q11.2)]]
|[[t(9;22)(q34;q11.2)]]
−|[[CML]],[[ B-ALL]],[[ T-ALL]]
+|[[CML]],[[ B-ALL]],[[T-ALL]]
|[[ABL1(ABL)-BCR]]
|[[ABL1(ABL)-BCR]]
|-
|-
|[[t(11;14)(q13;q32)]]
|[[t(11;14)(q13;q32)]]
|[[MCL]],[[ MM]]
|[[MCL]],[[ MM]]
−|[[CCND1(BCL1)- IGH]]
+|[[IGH-CCND1]]
|-
|-
|[[t(11;14)(q23;q32)]]
|[[t(11;14)(q23;q32)]]
−|[[t-AML]]
+|[[AML]]
|[[KMT2A-KIAA0284]]
|[[KMT2A-KIAA0284]]
|-
|-